Stargardt Disease clinical trials at UCSF
1 research study open to eligible people

  • Safety and Efficacy of Emixustat in Stargardt Disease

    open to eligible people ages 16 years and up

    The purpose of this study is to determine if emixustat hydrochloride reduces the rate of progression of macular atrophy compared to placebo in subjects with Stargardt disease.

    San Francisco, California and other locations

Last updated: